Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis.

Trial Profile

A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms PRISTINE
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Aug 2017 Results of pooled analysis of 10 trials (NCT00245960, NCT00111449, NCT00663052, NCT00454584) generating evidence concerning the number of patients dropping out of etanercept trials published in the British Journal of Dermatology
    • 20 Apr 2012 Actual end date (1 Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top